SELLAS FY2023 net loss $37.3M; SLS009 shows 50% response rate in r/r AML

SELLAS Life Sciences Group, Inc.

Net loss $37.3M ($1.34/sh) vs. $41.3M ($2.13/sh) in 2022; R&D expense $24.0M.
Cash at Dec 31, 2023: $2.5M; subsequent $9M (Jan) and $20M (Mar 2024) raised.
Phase 2a SLS009 in r/r AML: 50% response at 30mg BIW optimal dose; 100% in biomarker patients.
Phase 3 REGAL (GPS) enrollment completed; IDMC meeting late April; interim analysis possible in 1H2024.
Phase 1b/2 SLS009 in PTCL top-line data expected 1H2024; first DLBCL combo patient dosed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2023 and providing a corporate update.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.